Thienyl and Phenyl α-Halomethyl Ketones: New Inhibitors of Glycogen Synthase Kinase (GSK-3β) from a Library of Compound Searching

Journal of Medicinal Chemistry

Volumn 46, Issue 22, 2003, Pages 4631-4633

  Conde, Santiago ^a   Pérez, Daniel I ^a   Martínez, Ana ^a,b   Perez, Concepción ^a   Moreno, Francisco J ^c  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b NeuroPharma SA   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOACETYLTHIOPHENE DERIVATIVE; CHLOROACETYLHALOTHIOPHENE DERIVATIVE; CHLOROACETYLPHENYL DERIVATIVE; CHLOROMETHYLTHIENYL KETONE DERIVATIVE; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR; METHYLPHENYL KETONE DERIVATIVE; PHENYLMETHYL KETONE DERIVATIVE; THIENYL KETONE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME MECHANISM; IC 50; PROTEIN LOCALIZATION; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; DATABASES, FACTUAL; GLYCOGEN SYNTHASE KINASE 3; KETONES; KINETICS; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0142060928     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm034108b     Document Type: Article

References (30)

1. Olson, R. E.; Thompson, L. A. Chapter 4. Secretase Inhibitors as therapeutics in Alzheimer's Disease. Annu. Rep. Med. Chem. 2000, 35, (Chapt. 4) 31-40.
2. Grutzendler, J.; Morris, J. C. Cholinesterase inhibitors for Alzheimer's Disease. Drugs 2001, 61, 41-52.
3. Mudher, A.; Lovestone, S. Alzheimer's Disease - do tauists and baptists finally shake hands? Trends Neurosci. 2002, 25, 22-26.
4. Hellström-Lindahl, E. Modulation of β-amyloid precursor protein processing and tau phosphorylation by acetylcholine receptors. Eur. J. Pharmacol. 2000, 393, 255-263.
5. Mandelkow, E.-M.; Mandelkow, E. Tau in Alzheimer's Disease. Trends Cell Biol. 1998, 8, 425-427.
6. Ishiguro, K.; Ihara, Y.; Uchida, T.; Imahori, K. A novel tubulin-dependent protein kinase forming a paired helical filament epitope on tau. J. Biochem. (Tokyo) 1998, 104, 319-321.
7. Jicha, G. A.; Weaver, C.; Lane, E.; Vianna, C.; Kress, Y.; Rockwood, J.; Davies, P. cAMP-dependent protein kinase phosphorylations on tau in Alzheimer's disease. J. Neurosci. 1999, 19, 7486-7494.
8. Singh, T. J.; Grundke-Iqbal, I.; Wu, W. Q.; Chauhan, V.; Novak, M.; Kontzekova, E.; Iqbal, K. Protein kinase C and calcium/ calmodulin-dependent protein kinase II phosphorylate three-repeat and four-repeat tau isoforms at different rates. Mol. Cell. Biochem. 1997, 167, 141-148.
9. Imahori, K.; Uchida, T. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J. Biochem. 1997, 121, 179-188.
10. Ishiguro, K.; Shiratsuchi, A.; Sato, S.; Omori, A.; Arioka, M.; Kobayashi, S.; Uchida, T.; Imahori. K. Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett. 1993, 325, 167-172.
11. Ishiguro, K.; Kobayashi, S.; Omori, A.; Takamatsu, M.; Yonekura, S.; Anzai, K.; Imahori, K.; Uchida, T. Identification of the 23 kDa subunit of tau protein kinase II as a putative activator of cdk5 in bovine brain. FEBS Lett. 1994, 342, 203-208.
12. Doble, B. W.; Woodgett, J. R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 2003, 116, 1175-1186.
13. Kaytor, M. D.; Orr, H. T. The GSK3β signaling cascade and neurodegenerative disease. Curr. Opin. Neurobiol. 2002, 12, 275-278.
14. Planel, E.; Sun, X.; Takashima, A. Role of GSK-3β in Alzheimer's Disease pathology. Drugs Dev. Res. 2002, 56, 491-510.
15. Dorronsoro, I.; Castro, A.; Martínez, A. Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs? Exp. Opin. Ther. Patents 2002, 12, 1527-1536.
16. Phiel, C. J.; Wilson, C. A.; Lee, V. M.; Klein, P. S. GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature 2003, 423, 435-439.
17. De Strooper, B.; Woodgett, J. Alzheimer's disease: mental plaque removal. Nature 2003, 423, 392-393.
18. Mettey, Y.; Gompel, M.; Thomas, V.; Garnier, M.; Leost, M.; Ceballos-Picot, I.; Noble, M.; Endicott, J.; Vierfond, J.-M.; Meijer, L. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J. Med. Chem. 2003, 46, 222-236.
19. Smith, D. G.; Buffet, M.; Fenwick, A. E.; Haigh, D.; Ife, R. J.; Saunders: M.; Slingsby, B. P.; Stacey, R.; Ward, R. W. 3-Anilino-4-arylmaleimides: Potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. 2001, 11, 635-639.
20. Leost, M.; Schultz, C.; Link, A.; Wu, Y. Z.; Biernat, J.; Mandelkow, E. M.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Zaharevitz, D. W.; Gussio, R.; Senderowicz, A. M.; Sausville, E. A.; Kunick, C.; Meijer, L. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 2000, 267, 5983-5994.
21. Leclerc, S.; Garnier, M.; Hoessel, R.; Marko, D.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Biernat, J.; Wu, Y. Z.; Mandelkow, E. M.; Eisenbrand, G.; Meijer, L. Indirubins inhibit glycogen synthase kinase-3β and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. 2001, 276, 251-260.
22. Meijer, L.; Thunnissen, A. M.; White, A. W.; Garnier, M.; Nikolic, M.; Tsai, L. H.; Walter, J.; Cleverley, K. E.; Salinas, P. C.; Wu, Y. Z.; Biernat, J.; Mandelkow, E. M.; Kim, S. H.; Pettit, G. R. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 2000, 7, 51-63.
23. Martínez, A.; Alonso, M.; Castro, A.; Pérez, C.; Moreno, F. J. First Non-ATP Competitive Glycogen synthase kinase 3 β (GSK-3β) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem. 2002, 45, 1292-1299.
24. Woodgett, J. R. Use of peptide substrates for affinity purification of protein-serine kinases. Anal. Biochem. 1989, 180, 237-241.
25. Conde, S.; Corral, C.; Madroñero, R.; Sánchez Alvarez-Insúa, A. S. Fernández-Tomé, M. P.; del Rio, J.; Santos, M. β-Adrenoceptor blocking activity of halogenated thienylethanolamine derivatives. J. Med. Chem. 1977, 20, 970-974.
26. del Agua, M. J.; Alvarez-Insúa, A. S.; Conde, S. Bromothiophene reactions I. Friedel-Crafts acylation. J. Heterocycl. Chem. 1981, 18, 1345-1347.
27. Alvarez-Insúa, A. S.; Conde, S.; Corral, C. Bromothiophene Reactions II. a novel rearrangement in the zinc and acetic acid reduction. J. Heterocycl. Chem. 1982, 19, 713-716.
28. Powers, J. C.; Asgian, J. L.; Ekici, Ö. D.; James, K. E. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem. Rev. 2002, 102, 4751-4804.
29. Rauber, P.; Angliker, H.; Walker, B.; Shaw, E. The synthesis of peptidylfluoromethanes and their properties as inhibitors of serine proteinases and cysteine proteinases. Biochem. J. 1986, 239, 633-640.
30. Drenth, J.; Kalk, K. H.; Swen, H. M. Binding of chloromethyl ketone substrate analogues to crystalline papain. Biochemistry 1976, 24, 3731-3738.